PI3K/p110α inhibition selectively interferes with arterial thrombosis and neointima formation, but not re-endothelialization: potential implications for drug-eluting stent design by Holy, Erik W. et al.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
CLINICAL RESEARCH
PI3K/p110a inhibition selectively interferes with
arterial thrombosis and neointima formation, but
not re-endothelialization: potential implications
for drug-eluting stent design
Erik W. Holy1,2,3,4, Philipp Jakob1,2,3, Thomas Eickner5, Giovanni G. Camici2,3,
Ju¨rg H. Beer4, Alexander Akhmedov2,3, Katrin Sternberg5, Klaus-Peter Schmitz5,
Thomas F. Lu¨scher1,2,3, and Felix C. Tanner1,2,3*
1Cardiology, Cardiovascular Center, University Hospital Zu¨rich, Ra¨mistrasse 100, Zurich 8091, Switzerland; 2Cardiovascular Research, Physiology Institute, University of Zu¨rich, Zurich,
Switzerland; 3Center for Integrative Human Physiology,Universityof Zu¨rich, Zurich, Switzerland; 4Cantonal Hospital Baden, Baden, Switzerland; and 5Institute forBiomedical Engineering,
University of Rostock, Rostock, Germany
Received 18 July 2013; revised 19 September 2013; accepted 23 October 2013; online publish-ahead-of-print 11 December 2013
This paper was guest edited by Michael Joner MD (michaeljoner@me.com)
Background Impaired re-endothelialization and stent thrombosis are a safety concern associated with drug-eluting stents (DES). PI3K/
p110a controls cellular wound healing pathways, thereby representing an emerging drug target to modulate vascular
homoeostasis after injury.
Methods
and results
PI3K/p110awas inhibited by treatment with the small molecule inhibitor PIK75 or a specific siRNA. Arterial thrombosis,
neointima formation, and re-endothelialization were studied in a murine carotid artery injury model. Proliferation and
migration of human vascular smooth muscle cell (VSMC) and endothelial cell (EC) were assessed by cell number and
Boyden chamber, respectively. Endothelial senescence was evaluated by the b-galactosidase assay, endothelial dysfunc-
tion by organ chambers for isometric tension. Arterial thrombus formation was delayed in mice treated with PIK75 when
compared with controls. PIK75 impaired arterial expression and activity of tissue factor (TF) and plasminogen activator
inhibitor-1 (PAI-1); in contrast, plasma clotting and platelet aggregation did not differ. In VSMC and EC, PIK75 inhibited
expression and activity of TF and PAI-1. These effects occurred at the transcriptional level via the RhoA signalling cascade
and the transcription factor NFkB. Furthermore, inhibition of PI3K/p110a with PIK75 or a specific siRNA selectively
impaired proliferation and migration of VSMC while sparing EC completely. Treatment with PIK75 did not induce endo-
thelial senescence nor inhibit endothelium-dependent relaxations. In line with this observation, treatment with PIK75
selectively inhibited neointima formation without affecting re-endothelialization following vascular injury.
Conclusion Following vascular injury, PI3K/p110a inhibition selectively interferes with arterial thrombosis and neointima formation,
but not re-endothelialization. Hence, PI3K/p110a represents an attractive new target in DES design.
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Introduction
Vascular injury may either occur in response to mechanical forces
exerted by the circulation of blood or as a result of revascularization
procedures, i.e. percutaneous transluminal coronary angioplasty
(PTCA) or surgical endarterectomy and handling of bypass vessel.
Under all circumstances, vascular injury may either heal with
proper re-endothelialization or in certain cases lead to scar for-
mation with luminal narrowing and/or thrombotic occlusion. With
the increasing use of stents procedure-related vascular injury and
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restrictive remodelling leading to restenosis has become a siginficant
problem.1 Thus, stents designed to release antiproliferative agents
have been developed. Although the introduction of rapamycin- and
paclitaxel-eluting stents has resulted in a significant reduction of re-
stenosis and target-vessel revascularization compared with bare-
metal stents (BMS),2 –5 drug-eluting stents (DES) have failed to
improve mortality and were associated with increased stent throm-
bosis rates.6 –8 Impaired re-endothelializationaswell asprothrombo-
tic effects of the eluted drugs seems to play important roles under
these conditions.9 Thus, ideally DES should release drugs that select-
ively inhibit vascular smooth muscle proliferation and thrombus for-
mation, while allowing proper re-endothelialization still to occur.10
By catalysing the synthesis of phosphatidylinositol second messen-
gers (PIP, PIP2, and PIP3), the phosphatidylinositol-3 kinase (PI3K)
signalling pathway controls fundamental cellular processes such as
cell survival, proliferation, and differentiation.11 The class I PI3Ks
consist of a dimer with a regulatory (p85a) and a catalytic subunit
(p110a, p110b, and p110d). Class I PI3Ks are activated by tyrosine
kinases or G-protein coupled receptors and catalyse the generation
of PIP3, which modulates downstream targets such as the Rho
GTPases or the Akt/PDK1 pathway.11 The involvement of the
PI3Ks in pathophysiological processes such as cancer, inflammation,
or thrombosis has rendered these enzymes attractive therapeutic
targets and recent efforts have been taken to synthesize cell-
permeable small molecule PI3K inhibitors such as the PI3K/p110a
inhibitor PIK75.12,13 However, because of their ubiquitous distribu-
tion, the understanding of how the several PI3K isoforms control
pathophysiological responses and whether some provide selectivity
for certain vascular processes remains an important issue in the
development of PI3K-targeting drugs.
In the vasculature, the PI3K/p110a isoform is abundantly
expressed in endothelial cell (EC) and vascular smooth muscle cell
(VSMC). This study was designed to address the role of p110a in
injury-induced arterial thrombus formation. Since VSMC and EC
proliferation as well as migration are critically involved in vascular
healing following coronary intervention, we also investigated the
contribution of PI3K/p110a in those responses.
Methods
Expanded methods are provided in Supplementary material online.
Carotid artery thrombosis model
All animal procedures were approved by the local ethical committee
(Kantonales Veterina¨ramt Zu¨rich, Switzerland) and performed in ac-
cordance with institutional guidelines. Ten-week-old male C57Bl6 mice
weighing on average 27 g received a daily i.p. injection of PIK75 (10 mg/
kg body weight, Axon Medchem; Groningen, The Netherlands) or
vehicle (0.5% methylcellulose plus 15% dimethylsulfoxide) for 7 days.
Thrombus formation was induced by photochemical injury 24 h after
the last injection. Mice were anaesthetized by i.p. injection of sodium
pentobarbital (87 mg/kg; Butler, Columbus, OH, USA). Rose bengal
(Fisher Scientific, Fair Lawn, NJ, USA) was diluted in phosphate-buffered
saline (PBS) and then injected into the tail vein at a final concentration of
50 mg/kg. The right common carotid artery was exposed following a
midline cervical incision and the blood flow monitored using a Doppler
flow probe (Model 0.5 VB, Transonic Systems, Ithaca, NY, USA) con-
nected to a flowmeter (Model T106, Transonic Systems). Photochemical
injury was induced by a 1.5 mW green light laser (540 nm; Melles Griot,
Carlsbad, CA, USA) 6 min after i.v. rose bengal injection. From the onset
of injury, blood flow was monitored until occlusion occurred, which was
defined as flow ,0.1 mL/min for at least 1 min.
Cell culture
Human aortic endothelial cell (HAEC), human aortic smooth muscle cell
(AoSMC), and human umbilical vein endothelial cell (HUVEC; all from
Lonza, Basel, Switzerland) were cultured as described.14,15 Saphenous
vein smooth muscle cells (SVSMC) were isolated from human saphenous
veins, characterized, and cultured as described.16 Briefly, AoSMC and
SVSMC were grown on flasks (BD Biosciences, Bedford, MA, USA) in
Dulbecco’s modified Eagle’s medium (Invitrogen, Basel, Switzerland)
plus 10% foetal calf serum (FCS) using passages 5 to 9. Human aortic
endothelial cell and HUVEC were grown on fibronectin-coated
flasks in endothelial cell growth medium-2 (EGM-2) (Lonza) containing
10% FCS.
Peripheral blood mononuclear cells
Peripheral blood mononuclear cells (PBMCs) were isolated from healthy
human donors by density centrifugation in BD vacutainercell preparation
tubes with sodium heparin (Becton Dickinson, Franklin Lakes, NJ, USA)
and purified by magnetic cell sorting using anti-human CD14 antibody
(Miltenyi Biotec, Cologne, Germany) conjugated with magnetic beads.
Monocyte purity was assessed by flow cytometry (FACSCanto, BD,
Heidelberg, Germany). Monocytes were cultured in RPMI-1640 med-
ium (Invitrogen) containing 25 mM HEPES supplemented with 10%
FCS. PBMCs were incubated with PIK75 (0.1–10 nM) for 24 h following
starvation.
Generation of recombinant adenoviruses
and adenoviral infection
Recombinant adenoviruses were generously provided by Prof. Zihong
Yang (Department of Physiology, University of Fribourg, Fribourg, Switz-
erland).17 Cells were transduced with the respective adenoviral vector at
moi 800. After a 24-h growth period, the cells were rendered quiescent
for 24 h before harvesting.
Neointima formation
To investigate the impact of PIK75 treatment on neointima formation in
vivo, 10–14-week-old male C57Bl6 mice weighing on average 22–25 g
were anaesthetized by inhalation of 3% isoflurane. The left common
carotid artery was dissected and ligated near the carotid bifurcation as
previously described.18 Importantly, all animals recovered and showed
no symptoms of a stroke. Animals received a daily i.p. injection of
PIK75 (10 mg/kg body weight, Axon Medchem; Groningen, The Nether-
lands) or vehicle (0.5% methylcellulose plus 15% dimethylsulfoxide) for
14 days. After 2 weeks, animals were euthanized and the isolated arteries
werefixedwith4%paraformaldehyde inPBS.The commoncarotid arter-
ies were 8–10 mm long. Proximal and distal segments (2 mm) were dis-
carded and the remaining portion was embedded in paraffin. Serial
sections (5 mm thick) were cut for haematoxylin–eosin staining. Neoin-
tima formation was quantified by determining the mean neointima/media
ratio in triplicates of each sample.
Senescence-associated b-galactosidase assay
Human aortic endothelial cells were plated on fibronectin-coated
six-well dishes and grown for 24 h to 80% confluence in EGM-2 plus
10% FCS. After replacing the medium (EGM-2 plus 10% FCS), cells
were treated with vehicle (0.1% dimethylsulfoxide), PIK75 (10 nM), rapa-
mycin (10 nM), or paclitaxel (10 nM) for another 24 h. Human aortic
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endothelial cells were washed three times with PBS and fixed with 3%
paraformaldehyde for 3 min, incubated with a senescence-associated
b-galactosidase (SA-b-gal) stain solution for 14 h, and the proportion
of SA-b-gal positive cells determined as previously described.19
Endothelial function studies
Aortas obtained from male C57Bl6 mice were cut into rings (2–3 mm
long). Each ring was connected to an isometric force transducer (Multi-
Myograph 610M; Danish Myo Technology, Aarhus, Denmark), sus-
pended in an organ chamber filled with 5 mL of control solution (378C,
pH 7.4), and bubbled with 95% O2 and 5% CO2. Isometric tension was
recorded continuously. After a 30-min equilibration period, rings were
gradually stretched to the optimal point of their length–tension curve
as determined by the contraction to 60 mM KCl. Concentration-
dependent contractions were established by using norepinephrine
(NE) (1 nM–10 mM; Sigma Aldrich). Concentration–response curves
were obtained in a cumulative fashion. Several rings cut from the same
artery were studied in parallel. Responses to acetylcholine (1 nM–1 mM;
Sigma Aldrich) in the presence or absence of PIK75 (10 nM, 30 min)
were obtained during submaximal contraction to NE. The nitric oxide
(NO) donor sodium nitroprusside (0.1 nM–10 mM; Sigma Aldrich) was
added to test endothelium-independent relaxations. Relaxations were
expressed as a percentage of the pre-contracted tension.
In vivo re-endothelialization assay
Male C57Bl6 mice aged 10–14weeks were anaesthetized by inhalation of
3% isoflurane. The left common carotid artery was exposed via an anter-
ior incision of the neck. The electric injury was applied to the distal part of
the common carotid artery. The carotid artery was injured by electric
current with a bipolar microregulator. (ICC50, ERBE-Elektromedizin
GmbH, Tuebingen, Germany). An electric current of 2 W was applied
for 2 s to each millimetre of the carotid artery over a total length of
exactly 4 mm with the use of a size marker parallel to the carotid
artery. Following the injury animals received a daily i.p. injection of
PIK75 [10 mg/kg body weight, rapamycin (2 mg/kg body weight; Sigma
Aldrich)] or the vehicle. Three days after carotid injury, endothelial re-
generation was evaluated by 50 mL of solution containing 5% Evans
blue diluted in saline and injected into the tail vein 10 min before eutha-
nization. The left common carotid artery was dissected with an adjacent
portion of the carotid bifurcation and fixed with 4% paraformaldehyde in
PBS. The re-endothelialized area was calculated as difference between
the blue-stained area and the injured area by computer-assisted morpho-
metric analysis.
Statistical analysis
Data are presented as means+ SEM. Means were compared between
two groups using the non-parametric Mann–Whitney U test. For mul-
tiple comparisons the analysis of variance (ANOVA) test followed by
Bonferroni’s correction was applied. A value of P, 0.05 was considered
significant. All P-values are two-sided. Statistics were performed using the
GraphPad prism 6.0 Software (GraphPad Software, Inc., La Jolla, CA,
USA).
Results
PI3K/p110a inhibition delays
injury-induced arterial thrombus
formation in vivo
Treatment with PIK75 was well tolerated and no differences in body
weight, liver enzyme activities, and lipid profiles were observed
between the treatment and control group (data not shown).
HPLC-MS analysis demonstrated that plasma levels of PIK75 2 and
24 h after i.p. injection peaked at 116.9+13.8 and 17.33+
0.65 nM, respectively.
Arterial thrombus formation was studied in male C57Bl6 mice
using a carotid artery photochemical injury model as described
above. Time to thrombotic occlusion was delayed in animals
treated with PIK75 when compared with controls (n ¼ 7; P, 0.01,
Figure 1A). Clotting assays demonstrated that this effect was not par-
alleled by changes in prothrombin time (P ¼ 0.47), activated partial
thromboplastin time (P ¼ 0.33), or platelet aggregation in response
to ADP (P ¼ 0.07) or collagen (P ¼ 0.77) (n ¼ 7, Supplementary ma-
terial online, Figure S1A–D). In addition, treatment with PIK75 for
7 days had no effect on tail bleeding time (n ¼ 7; control 52+5 s,
PIK75 57+4 s; P ¼ 0.39). Real-time PCR analysis of carotid arteries
demonstrated a decreased tissue factor (TF) and plasminogen activa-
tor inhibitor-1 (PAI-1) mRNA expression in PIK75-treated animals
when compared with controls (n ¼ 8; P, 0.05; Figure 1B and C ).
This effect was paralleled by a reduced TF and PAI-1 activity in the
tissue lysates (n ¼ 8; P, 0.05; Figure 1D and E). In contrast, TF
pathway inhibitor (TFPI) and tissue plasminogen activator (t-PA)
mRNA levels did not differ between the groups (n ¼ 8; P ¼ 0.52
and P ¼ 0.53, respectively; Supplementary material online, Figure
S1E and F ).
PI3K/p110a promotes TF and PAI-1
expression in vascular cells and monocytes
PIK75 (0.1–10 nM) inhibited TNF-a-induced TF expression in
HAEC as well as basal TF expression in AoSMC in a concentration-
dependent manner (n ¼ 4; P, 0.05; Figure 2A and B). In PBMC treat-
ment with PIK75 resulted in a similar concentration-dependent de-
crease in TF expression (n ¼ 4; P, 0.05; Supplementary material
online, Figure S2). PIK75 also strongly impaired PAI-1 expression in
HAEC and AoSMC (n ¼ 4; P, 0.05; Figure 2C and D). No cytotoxic
effect of PIK75 was observed in any of these cell types at any of the
concentrations used (n ¼ 4; data not shown).
To investigate the contribution of the other PI3K isoforms in TF
and PAI-1 expression, HAEC and AoSMC were incubated with
corresponding specific small molecule inhibitors. In contrast to
the inhibitory effect of PIK75, pharmacological inhibition of PI3K/
p110b,g, and dwith TGX221, AS605240, and IC87114, respectively,
resulted in a further stimulation of TNF-a-induced TF expression in
HAEC (n ¼ 4; P, 0.05; Figure 2E). In AoSMC, PIK75, decreasedbasal
TF expression, while inhibitors of PI3K/p110b, g, and d had no effect
(n ¼ 4; P, 0.05; Figure 2F).
PI3K/p110a silencing mimics the effect
of PIK75 on TF and PAI-1
Treatment of AoSMC and HAEC with siRNA targeting p110amark-
edly decreased p110a protein expression in both cell types (n ¼ 4;
P, 0.01; Supplementary material online, Figure S3A and B). Silencing
of PI3K/p110a was paralleled by an inhibition of TF expression in
HAEC as well as in AoSMC (n ¼ 4; P, 0.05; Figure 3A and B). Inhib-
ition of PI3K/p110a with siRNA also decreased PAI-1 expression in
both cell types (n ¼ 4; P, 0.05; Figure 3C and D).
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PI3K/p110a promotes TF and PAI-1
transcription via RhoA-GTPase and NFkB
In AoSMC and HAEC, treatment with PIK75 or siRNA targeting
p110a decreased TF and PAI-1 mRNA expression (n ¼ 4; P,
0.05; Figure 4A and D). Pull-down assays demonstrated that pharma-
cological inhibition of PI3K/p110a reduced activity of the GTPase
RhoA and the transcription factor NFkB in both cell types (n ¼ 4;
P, 0.05; Figure 4B and E). Activation of the mitogen-activated
protein (MAP-)kinases was not affected by PI3k/p110a inhibition in
none of the cell types (n ¼ 4; data not shown).
A role of RhoA in mediating the induction of TFand PAI-1 was con-
firmed by adenoviral overexpression of the constitutively active
RhoA mutant Rho63 which enhanced both basal TF and PAI-1 ex-
pression in AoSMC and TNF-a-induced TF and PAI-1 expression
in HAEC, while overexpression of the dominant negative mutant
Rho19 inhibitied TF and PAI-1 expression in both cell types (n ¼ 4;
P, 0.05; Figure 4C and F ).
PI3K/p110a regulates vascular smooth
muscle cell proliferation, chemotaxis, and
neointima formation in vivo
Since the RhoA-GTPase has been shown to play important roles
in the proliferative potential of vascular SMC, the impact of
PI3K/p110a inhibition on the proliferative properties of vascular
SMC was further investigated. Treatment with PIK75 (0.1–10 nM)
inhibited PDGF-BB-induced proliferation of AoSMC in a
concentration-dependent manner as well as migration of AoSMC
(n ¼ 4; P, 0.05; Figure 5A). Experiments performed in venous
Figure 1 PI3K/p110a inhibition impairs arterial thrombus formation. (A) Time to thrombotic occlusion following photochemical injury of the
carotid artery is delayed in animals treated with PIK75 (10 mg/kg bodyweight, 7 days) when compared with controls (n ¼ 7; *P, 0.01). (B and
C) Real-time PCR analysis demonstrates a reduced tissue factor (TF) and plasminogen activator inhibitor-1 (PAI-1) mRNA expression in carotid
artery tissue lysates from PIK75-treated animals when compared with controls (n ¼ 8; *P, 0.05). (D and E) Treatment with PIK75 reduces TF
and PAI-1 activity in carotid artery tissue lysates (n ¼ 8; *P, 0.05).
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Figure 2 PI3K/p110a regulates tissue factor and plasminogen activator inhibitor-1 expression in vascular cells. (A) PIK75 inhibits TNF-a-induced
TFexpression in human aortic endothelial cell in a concentration-dependent manner (n ¼ 4; *P, 0.05). (B) In aortic smooth muscle cell PIK75 (0.1–
10 nM) abrogates basal TF expression (n ¼ 4; *P, 0.05). (C and D) PIK75 inhibits PAI-1 expression in human aortic endothelial cell (C) and aortic
smooth muscle cell (D) (n ¼ 4; *P, 0.05). (E) In contrast toPIK75, pharmacological inhibition ofPI3K/p110b,g, anddwith TGX 221,AS602240, and
IC87114, respectively, enhances TNF-a-induced TF expression in human aortic endothelial cell (n ¼ 4; *P, 0.05). (F) In aortic smooth muscle cell,
solely PIK75 decreased basal TF expression (n ¼ 4; *P, 0.05).
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SMC (SVSMC) obtained from the saphenous vein confirmed the
results obtained in AoSMC (n ¼ 4, Supplementary material online,
Figure S4A and C ). In line with this observation, silencing of PI3K/
p110a by siRNA decreased proliferation and impaired chemotaxis
of AoSMC in response to PDGF-BB (n ¼ 4; P, 0.01 vs. control;
Figure 5B). Treatment with PIK75 (10 nM), rapamycin (10 nM), or
paclitaxel (10 nM) resulted in a comparable inhibition of
PDGF-BB-induced proliferation and migration of AoSMC (n ¼ 4;
P, 0.005; Figure 5C).
To confirm the relevance of the antiproliferative effects of PIK75
observed at the cellular level in vivo, injury-induced neointima forma-
tion was studied in a murine carotid artery ligation model. Twoweeks
after ligation of the carotid artery neointimal hyperplasia was
observed in the carotid arteries of control animals (n ¼ 6;
Figure 5D). Treatment with PIK75 or rapamycin inhibited neointima
formation following vascular ligation as determined by the assess-
ment of the intima/media ratio by (n ¼ 6; P, 0.01 vs. control;
Figure 5D and E).
Figure 3 PI3K/p110a silencing inhibits tissue factor and plasminogen activator inhibitor-1. (A and B) Silencing of PI3K/p110awith siRNA inhibits
TF expression in human aortic endothelial cell as well as in aortic smooth muscle cell (n ¼ 4; *P, 0.05). (C and D) Inhibition of PI3K/p110a with
siRNA also decreased PAI-1 expression in both cell types (n ¼ 4; *P, 0.05).
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Figure 4 PI3K/p110a regulates tissue factor (TF) and plasminogen activator inhibitor-1 (PAI-1) transcription via RhoA-GTPase and NFkB. Treatment with PIK75 (10 nM) or siRNA targeting p110a
inhibits TF and PAI-1 mRNA expression in aortic smooth muscle cell (A; n ¼ 4; *P, 0.05) and human aortic endothelial cell (D; n ¼ 4, *P, 0.05). Inhibition of PI3K/p110awith PIK75 reduces activity of
the RhoA-GTPase and the transcription factor NFkB under basal conditions in aortic smooth muscle cell (B; n ¼ 4; *P, 0.05) and in TNF-a stimulated human aortic endothelial cell (E; n ¼ 4, *P, 0.05).
(C and F) Adenoviral overexpression of the constitutively active RhoA mutant Rho63 enhances TF and PAI-1 expression in aortic smooth muscle cell (n ¼ 4; *P, 0.05 vs. control) and human aortic
endothelial cell (n ¼ 4; *P, 0.05 vs. TNF-a), while overexpression of the dominant negativemutant Rho19 blunts TFand PAI-1 expression in aortic smooth muscle cell (n ¼ 4; *P, 0.05 vs. control) and
human aortic endothelial cell (n ¼ 4; **P, 0.01 vs. TNF-a).
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PI3K/p110a inhibition does not affect
endothelial proliferation, chemotaxis,
and nirtic oxide synthesis
Treatment with PIK75 (0.1–10 nM) did not affect serum-induced
proliferation and migration of HAEC (n ¼ 4; Figure 6A). Consistent
with this observation, silencing of PI3K/p110a had no impact on
endothelial proliferation and migration capacity (n ¼ 4; Figure 6B).
Experiments performed in HUVEC confirmed the results obtained
in arterial EC (n¼ 4; Supplementary material online, Figure S4B and D).
In contrast to PIK75, the mTOR inhibitors rapamycin and paclitaxel
exerted anti-proliferative and anti-migratory effects in ECs (n ¼ 4;
P, 0.005; Figure 6C).
Since down-regulation of endothelial NO expression (eNOS) ex-
pression is critically involved in both endothelial proliferation and mi-
gration, eNOS expression was assessed in HAEC by western blot.
Rapamycin and paclitaxel, but not PIK75, decreased total eNOS ex-
pression in HAEC within 24 h (n ¼ 4; P, 0.005; Figure 6D), resulting
in impaired endogenous NO production in HAEC (n ¼ 4; P, 0.05,
Figure 6E).
Figure 5 PI3K/p110a regulates vascular smooth muscle cell proliferation, chemotaxis, and neointima formation. (A) PIK75 inhibits
PDGF-BB-induced proliferation and migration of aortic smooth muscle cell in a concentration-dependent manner (n ¼ 4; *P, 0.05). (B) Silencing
of PI3K/p110aby siRNA inhibited the proliferation and chemotaxis of aortic smooth muscle cell in response to PDGF-BB in a similar manner (n ¼ 4;
*P, 0.01 vs. PDGF-BB). (C) Treatment with PIK75, rapamycin, or paclitaxel results in a similar inhibition of PDGF-BB-induced proliferation and
migration (n ¼ 4; *P, 0.005 vs. PDGF-BB). (D) Treatment with PIK75 or rapamycin for 14 days inhibits neointima formation following vascular li-
gation when compared with untreated controls (representative photograph of carotid arteries stained with haematoxylin and eosin; M, media; NI,
neointima; black arrow indicates internal elastic membrane). (E) Antiproliferative effects of PIK75 and rapamycin were quantified by determing the
intima/media ratio (n ¼ 6; *P, 0.05 vs. control).
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PIK75 does not affect endothelial
senescence, function, and repair capacity
The decrease in eNOS expression observed in HAEC treated with
rapamycin and paclitaxel for 24 h was paralleled by the induction of
a senescent phenotype characterized by an enlarged and elongated
cellular morphology (Figure 7A). These morphological changes
were not observed with PIK75 (n ¼ 4; Figure 7A). The SA-b-gal
assay confirmed senescence in HAEC treated with rapamycin or
paclitaxel, but not in PIK75-treated cells (n ¼ 4; P, 0.05; Figure 7B).
Isometric tension studies in organ chambers demonstrated no dif-
ference in endothelium-dependent relaxations to acetylcholine
between aortas treated with PIK75 and controls (n ¼ 8; P ¼ 0.45.,
Figure 7C). Endothelium-independent relaxations to the NO donor
sodium nitroprusside were identical in both groups, denoting no dif-
ference in the response of VSMCs to NO (n ¼ 8; P ¼ 0.56.;
Figure 7D).
Consistent with those findings, endothelial healing in the carotid
artery 3 days after electric injury was not affected by pharmacological
inhibition of PI3K/p110a with PIK75 (n ¼ 6; P ¼ 0.38. vs. control;
Figure 7E and F). In contrast, treatment with rapamycin significantly
delayed endothelial repair following vascular injury (n ¼ 6; P,
0.01 vs. control and PIK75; Figure 7E and F ).
Rapamycin and paclitaxel, but not PIK75,
induce endothelial TF and PAI-1
expression
Treatment of HAEC with rapamycin (10 nM) or paclitaxel (10 nM)
induced basal TF expression (n ¼ 4; P, 0.05 vs. control; Figure 8A)
as well as TNF-a-induced TF expression (n ¼ 4; P, 0.05 vs.
TNF-a alone; Figure 8B). In contrast, PIK75 inhibited basal- and
TNF-a-induced TF expression (n ¼ 4; P, 0.01; Figure 8A and B). In
a similar manner, rapamycin and paclitaxel, but not PIK75, enhanced
basal PAI-1 expression in HAEC (n ¼ 4; P, 0.05; Figure 8C). Only
treatment with PIK75 abrogated TNF-a-induced PAI-1 expression
(n ¼ 4; P, 0.01 vs. TNF-a alone; Figure 8D).
Discussion
This study provides evidence for a functional diversity of PI3K/p110
isoforms. Specifically, we demonstrate that PI3K/p110a plays a
crucial role in the induction of pro-thrombotic proteins such as TF
andPAI-1viaRhoA-GTPaseandNFkB in vitro and in arterial thrombus
formation in vivo. Moreover, PI3K/p110a regulates proliferation and
migration of VSMCs via RhoA while sparing ECs.
The small molecule inhibitor PIK75 is an imidazopyridine devel-
oped in the context of a PI3-kinase drug discovery programme.13
PIK75 selectively inhibits the catalytic subunit p110a encoded by
the PIK3CA gene.20 The dose of PIK75 used for our in vivo studies
is within the range of that used in previously published studies
that demonstrated a potent inhibition of PI3K/p110a in several
PIK75-treated tissues.13 Measurement of plasma levels in our study
also provides evidence that the concentrations employed for the
experiments are in a pharmacologically relevant range. Several
studies have confirmed that at these in vivo concentration ranges,
PIK75 is a highly selective inhibitor of PI3K/p110a compared with
other class I PI3Kinases (p110b and p110d).13,20 Inhibition of the
three other PI3K isoforms resulted in induction rather than inhibition
of TF and PAI-1 expression in cultured vascular cells, which provides
evidence for the biological selectivity of different PI3K isoforms and
the pharmacological selectivity of different PI3K isoform inhibitors.
Based on results from previous in vivo studies and the plasma levels
measured in the present study, it is reasonable to assume that the
potent antithrombotic and antiproliferative effects observed after
treatment with PIK75 are mediated by inhibition of PI3K/p110a activ-
ity in the vessel wall even though PI3K/p110a activity was not directly
measured in carotid artery lysates.
A limitation of the present study is that only pharmacological inhib-
ition of PI3K/p110awas applied to investigate the role of PI3K/p110a
in thrombus formation in vivo. However, PIK75 is a highly specific in-
hibitor of PI3K/p110a and, to our knowledge, an appropriate genetic
model is not available. For instance, endothelial-specific homozygous
inactivation of PI3K/p110a causes embryonic lethality, while mice
heterozygous for the D910A knock-in mutation (p110aD933A/
WT) are viable and fertile, but display a strong metabolic phenotype
which would probably interfere with the study endpoint.21,22
Another potential limitation of the study is related to the observation
that performing experimental studies with a small number of animals
and a single strain carries the risk of over- or underestimating the bio-
logical effect observed.
Suppression of basal- and cytokine-induced TF and PAI-1 expres-
sion through PI3K/p110a inhibition is of particular relevance, since
both proteins are critically involved in the pathogenesis of stent
thrombosis.9 During acute coronary syndromes and PTCA, peripro-
cedural cytokine plasma levels are increased to concentrations high
enough to induced TF and PAI-1 expression in surrounding vascular
cells.23,24 While rapamycin and paclitaxel enhance both basal- and
TNF-a-induced TF and PAI-1 expression, PI3K/p110a inhibition
with PIK75 exerts potent antithrombotic effects. In vascular cells, in-
hibition of PI3K/p110a resulted in decreased expression of TF and
PAI-1 mediated by reduced activation of RhoA GTPase and the
transcription factor NFkB. The role of RhoA activation and NFkB
in regulating TF and PAI-1 has previously been described.25,26
Pharmacological inhibition of PI3K/p110a decreased expression
and activity of both TF and PAI-1 in the arterial wall without affecting
plasma clotting times and platelet aggregation. This indicates that
PI3K/p110a inhibition impairs local injury-induced arterial throm-
bosis by regulating the expression and activity of prothrombotic
mediators within the artery wall, rather than inducing any functionally
relevant alterations in the activity of plasmatic coagulation factors or
circulating platelets.
While a trend towards inhibition of platelet aggregation could be
observed in the treated group, this effect did not reach statistical sig-
nificance which may be due to the use of small sample sizes in the in
vivo studies potentially resulting in an underestimation of the effect.
Interestingly, a previous study described a role of PI3K/p110a in
insulin-like growth factor-1-mediated propagation of platelet activa-
tion after stimulation with the PAR-1 agonist SFLLRN.27 It is import-
ant to note that in contrast to the current study the direct effect of
PIK75 on ADP or collagen was not investigated in the cited study,
which renders side-by-side comparisons of the results difficult. In
addition, concentrations of PIK75 used in that study were significantly
higher than the one in our study, where concentrations in vitro as well
as in vivo peaked in the nanomolar range.
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Vascular smooth muscle cell proliferation and migration are crucial
cellular mechanisms triggering a response to injury and in turn resten-
osis in coronary arteries following PTCA and intimal hyperplasia and
occlusion of venous grafts after coronary artery bypass operations.28
In particular, the RhoA-GTPase has been shown to play an important
role in the proliferative response to mechanical stress in VSMC.29 To
confirm the in vivo relevance of the antiproliferative response to PI3K/
p110a inhibition, neointima formation was studied in an established
animal model. Murine models of restenosis based on arterial injury
carry the distinctive advantage of inducing smooth muscle-rich
neointimal hyperplasia while thrombus formation remains
limited.30 Complete ligation of the carotid artery near the carotid bi-
furcation has been shown to induce proliferation of smooth muscle
cells leading to significant neointima formation.18 Hence, this
model appears particularly suitable to investigate the antiproliferative
effects of PIK75 on VSMCs in vivo.
The PI3K family consists of several isoforms with regard to the
regulatory p85 and the catalytic p110 subunits. Studies on the
p85a/p110a dimer showed that the p85a regulatory subunit inhibits
the catalytic activity of p110a and that oncogenic p85amutations act
by disrupting the inhibitory contact with p110a.31,32 A more recent
study demonstrated that phosphorylation of p85a at serine 83
(pSer83) resulted in inhibition of VSMC and reduced neointima for-
mation after balloon injury without affecting endothelial regener-
ation.33 The present study demonstrates for the first time that
inhibition ofp110a is very likely tomediate this selective antiprolifera-
tive effect in VSMC. Since p85a can interact with different p110 iso-
forms and the expression of the p110 isoforms varies greatly
between tissues, modulation of p85a activity and consecutive regula-
tion of downstream cellular responses is likely complex and currently
not well understood. Inhibition of p110a instead offers the advantage
of targeting a single PI3K pathway and may be a safer option.
Delayed arterial healing manifested by impaired re-endothelializa-
tion and enhanced thrombogenicity remains a concern associated
with the use of DES, but is relevant for vascular injury and healing
at large. Morphological studies have indeed demonstrated a
Figure 6 PI3K/p110a inhibition is inert towards endothelial proliferation, chemotaxis, and nirtic oxide synthesis. (A) PIK75 does not exert any
inhibitory effect on proliferation or serum-induced chemotaxis in human aortic endothelial cell (n ¼ 5). (B) Silencing of PI3K/p110a has no
impact on endothelial proliferation and migration capacity (n ¼ 4). (C) In contrast to PIK75, rapamycin and paclitaxel exert anti-proliferative and
anti-migratory effects in endothelial cells (n ¼ 4; *P, 0.005). (D) Treatment with rapamycin and paclitaxel for 24 h, but not PIK75, decreases
eNOS expression in human aortic endothelial cell (n ¼ 4; *P, 0.005) and inhibits endogenous endothelial nitric oxide production (E; n ¼ 4;
*P, 0.05).
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marked delay of re-endothelialization with the use of both
rapamycin- and paclitaxel-eluting stents when compared with
BMS.34 Indeed, rapamycin and paclitaxel suppress EC proliferation
and migration as demonstrated in several studies.15,35 In addition,
by inducing a senescent phenotype and a decrease in eNOS expres-
sion, recent data suggest that those drugs impair endothelial
Figure 7 PIK75 does not affect endothelial senescence, eNOS expression and re-endothelialization capacity. (A) Rapamycin and paclitaxel, but
not PIK75 induce a senescent phenotype in human aortic endothelial cell (representative figure of four independent experiments).
(B) Senescence-associated b-galactosidase staining demonstrates senescence in human aortic endothelial cell treated with rapamycin or paclitaxel,
but not in PIK75-treated cells (n ¼ 4; *P, 0.05). (C) Isometric tension studies demonstrate no difference in endothelium-dependent relaxations to
acetylcholine betweenaortas treated with PIK75 and controls (n ¼ 8; P ¼ 0.45). (D) PIK75 had no effect on endothelium-independent relaxations to
the nitric oxide donor sodium nitroprusside (n ¼ 8; P ¼ 0.56). (E) Representative photographs of carotid arteries from mice. Endothelial injury was
confirmed by Evans blue dye staining (representative picture of six independent experiments. (F) In contrast to rapamycin, PIK75 did not impair
arterial re-endothelization after electrical injury (n ¼ 6; *P, 0.05).
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regrowth,19 Paclitaxel and rapamycin treated control groups were
not included in the organ chamber experiments in the context
of the current study since previous studies already convincingly
demonstrated that both compounds also affect endothelial
function.36–38 In line with this observation, rapamycin as well as pacli-
taxel exerts direct prothrombotic effects by enhancing both basal-
and cytokine-induced endothelial expression of TF and PAI-1.39,40
Most of these biological effects have also been observed with
Figure8 Rapamycin andpaclitaxel, but notPIK75, induceendothelial tissue factorandplasminogenactivator inhibitor-1expression.Rapamycinor
paclitaxel, but not PIK75, enhances basal TF expression (n ¼ 4; *P, 0.05;A) as well as TNF-a-induced TF expression (n ¼ 4; *P, 0.05;B). Similarly,
rapamycin and paclitaxel, but not PIK75, induce basal- (n ¼ 4; P, 0.05; C ) and TNF-a-induced PAI-1 expression (n ¼ 4; P, 0.01; D).
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compounds used for second generation DES and suggest that the
thrombotic risk of DES is a function of both impaired endothelial
coverage and function.41– 43
In contrast to rapamycin or paclitaxel, inhibition of p110a with
PIK75 or the corresponding siRNA did neither affect proliferation
nor migration of arterial or venous EC. While the current study
demonstrates that TF and PAI-1 expression are regulated by
RhoA-GTPase in both cell types, proliferation of EC does not
depend on RhoA and is rather regulated by the small GTPase
Rac-1.29 Hence, the decrease in RhoA activity observed in both cell
types is consistent with the selective interference of PI3K/p110a in-
hibition with VSMC proliferation. Mechanistically, Rac1 triggers pro-
liferative signalling through the p21-activated protein kinase and
microinjection of Rac1 has been shown to stimulate DNA synthe-
sis.44 Interestingly, PI3K/p110a-dependent activation of Rac-1 regu-
lates EC migration in response to hydrogen sulfide.45 Another
study suggested a regulatory role for PI3K/p110a in endothelial
barrier function via Rac-1 activation.46 While the same authors
demonstrated a crucial role for PI3K/p110a in developmental angio-
genesis, tube formation, and EC migration through the small GTPase
RhoA, they did not observe any inhibitory effect on EC proliferation,
which is in line with our observation as well as that of another group
demonstrating that PI3K/p110a also regulates Rac-1 in endothelial
cells.46,47
Inhibition of PI3K/p110a did neither affect endothelial NO gener-
ation nor endothelium-dependent vascular relaxation, which is of
particular interest since eNOS activation and endothelial NO gener-
ation are critically involved in endothelial repair in vivo.48 Nitric oxide
is a major regulator of EC migration and proliferation which is sup-
ported by the finding that NO is generated by EC upon stimulation
with VEGF and that deletion of the eNOS gene in knockout mice
results in impaired angiogenesis.49,50 Interestingly, the RhoA/Rho-
kinase pathway plays an important role in eNOS suppression in EC
leading to reduced NO synthesis. Transfection of EC with a dominant
negative RhoA mutant increases eNOS expression.51 In the current
study, we observed that inhibition of PI3K/p110a suppressed
TNF-a-induced RhoA activation in EC. Hence, it is conceivable
that PI3K/p110a may contribute to re-endothelialization by an
increased, or at least stable, NO production.
Finally, it is important to mention that the use of different chemoat-
tractants (i.e. VEGF, TNF-a, and serum) makes it difficult to compare
the results between the different in vitro studies. Re-endothelization
of injuredvessels in vivo involves several cellularmechanisms including
chemotactic, mechanotactic, and haptotactic migration as well as
proliferation of EC. In the current study, we demonstrate for the
first time that pharmacological inhibition of PI3K/p110a does not
affect the complex process of re-endothelialization following vascu-
lar injury, which is a particularly interesting observation in the context
of DESdesign.However, furthermolecular studieswill be required to
decrypt the cellular pathways underlying the cell-specific antiproli-
ferative effects of PI3K/p110a inhibition in different cell types.
In summary, the present study provides evidence that inhibition of
PI3K/p110a impairs arterial thrombus formation and differentially
regulates smooth muscle and endothelial cell activation. Since specif-
ic targeting of p110 isoforms is currently evaluated in different areas
of medicine, local inhibition of p110a might represent a novel strat-
egy in the context of DES design, in order to prevent restenosis
without adding the risk of impaired re-endothelialization and
enhanced thrombogenicity.
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Supplementary material is available at European Heart Journal online.
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